Company Profiles

driven by the PitchBook Platform

Igenica Biopharmaceuticals

Igenica Biopharmaceuticals
2008 FOUNDED
PRIVATE STATUS
21-30 EMPLOYEES
Series F LATEST DEAL TYPE
$5.95M LATEST DEAL AMOUNT
4 INVESTORS
Description

Developer of antibody-based therapeutics designed to offer treatment of cancer. The company's antibody-based therapeutics offers integrated innovative technology platforms to address the major challenges to developing effective treatments for multiple oncology indications, enabling cancer patients to get novel pipeline of immunotherapies.

Website
Formerly Known As
Igenica
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
863A Mitten Road
Suite 100B2
Burlingame, CA 94010
United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Igenica Biopharmaceuticals’s full profile, request a free trial.

Igenica Biopharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series F) 14-Oct-2015 $5.95M 000.00 Completed Clinical Trials - General
6. Later Stage VC (Series D) 21-Jan-2015 00.000 000.00 000.00 Completed Clinical Trials - General
5. Grant 07-Aug-2014 00000 000.00 Completed Clinical Trials - General
4. Later Stage VC (Series C) 28-Jan-2014 000.00 000.00 000.00 Completed Clinical Trials - General
3. Later Stage VC (Series C) 10-Jun-2013 000.00 000.00 000.00 Completed Pre-Clinical Trials
2. Early Stage VC (Series B) 13-Sep-2011 $16M $22.2M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 14-Dec-2009 $6.2M $6.2M 00.00 Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

Igenica Biopharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series D 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series C 00,000,000 00.000000 00 00 00 00 00 00.00
Series B 12,924,266 $0.001000 8% $1.25 $1.25 1x $1.25 11.83%
Series A 6,222,500 $0.001000 8% $1 $1 1x $1 5.7%
To view this company’s complete Cap Table, request access »

Igenica Biopharmaceuticals Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Third Rock Ventures Venture Capital Minority 000 0000 000000 0
5AM Ventures Venture Capital Minority 000 0000 000000 0
OrbiMed Venture Capital Minority 000 0000 000000 0
The Column Group Venture Capital Minority 000 0000 000000 0

Igenica Biopharmaceuticals Executive Team (10)

Name Title Board
Seat
Contact
Info
Hans Van Houte Chief Financial Officer
Thi-Sau Migone Ph.D Chief Scientific Officer
Guoqing Chen Ph.D Co-Founder & Vice President, Research
Robert Schreiber Ph.D Co-Founder & Board Member
Randall Halcomb Ph.D Vice President of Chemistry

3 Former Executives

You’re viewing 5 of 10 executives. Get the full list »

Igenica Biopharmaceuticals Board Members (5)

Name Representing Role Since Contact
Info
Carl Gordon Ph.D OrbiMed Board Member 000 0000
David Goeddel Ph.D The Column Group Chairman 000 0000
Gwen Fyfe MD Self Board Member 000 0000
John Diekman Ph.D 5AM Ventures Board Member 000 0000
Mark Goldsmith Ph.D Third Rock Ventures Board Member 000 0000
Questions or concerns about this profile? Reach out to website-support@pitchbook.com